Importer of Controlled Substances; Notice of Application, 64678-64679 [E7-22486]
Download as PDF
<![CDATA[
64678
Federal Register / Vol. 72, No. 221 / Friday, November 16, 2007 / Notices
Dated: November 6, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–22515 Filed 11–15–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated June 26, 2007, and
published in the Federal Register on
July 3, 2007, (72 FR 36481), Dade
Behring, Inc., 100 GBC Drive, MS514,
Post Office Box 6101, Attention: RA/GS,
Newark, Delaware 19714–6101, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedule I and II:
Drug
Schedule
Tetrahydrocannabinols (7370) .....
Benzoylecgonine (9180) ...............
Morphine (9300) ...........................
I
II
II
mstockstill on PROD1PC66 with NOTICES
The company plans to produce the
listed controlled substances in bulk to
be used in the manufacture of reagents
and drug calibrator/controls for DEA
exempt products.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of Dade
Behring, Inc. to manufacture the listed
basic class of controlled substance is
consistent with the public interest at
this time. DEA has investigated Dade
Behring, Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: November 5, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–22470 Filed 11–15–07; 8:45 am]
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
Importer of Controlled Substances;
Notice of Application
By Notice dated June 26, 2007, and
published in the Federal Register on
July 5, 2007, (72 FR 36729), Dade
Behring Inc., Regulatory Affairs, Quality
Systems, 20400 Mariani Avenue,
Cupertino, California 95014, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedule I and II:
Drug
Schedule
Tetrahydrocannabinols (7370) .....
Benzoylecgonine (9180) ...............
Morphine (9300) ...........................
The company plans to produce the
listed controlled substances in bulk to
be used in the manufacture of reagents
and drug calibrator/controls for DEA
exempt products.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of Dade
Behring, Inc. to manufacture the listed
basic classes of controlled substances is
consistent with the public interest at
this time. DEA has investigated Dade
Behring, Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: November 5, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–22477 Filed 11–15–07; 8:45 am]
BILLING CODE 4410–09–P
BILLING CODE 4410–09–P
VerDate Aug<31>2005
21:48 Nov 15, 2007
Jkt 214001
I
II
II
PO 00000
Frm 00105
Fmt 4703
Sfmt 4703
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II and prior
to issuing a registration under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with Title 21
Code of Federal Regulations (CFR),
1301.34(a), this is notice that on June
22, 2007, Fisher Clinical Services Inc.,
7554 Schantz Road, Allentown,
Pennsylvania 18106, made application
by renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of Noroxymorphone (9668),
a basic class of controlled substance
listed in schedule II.
The company plans to import the
listed substance for analytical research
and clinical trials.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43
and in such form as prescribed by 21
CFR 1316.47.
Any such comments or objections
being sent via regular mail should be
addressed, in quintuplicate, to the Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), Washington, DC
20537, or any being sent via express
mail should be sent to Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), 8701 Morrissette
Drive, Springfield, VA 22152; and must
be filed no later than December 17,
2007.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
§ 1301.34(b), (c), (d), (e) and (f). As
noted in a previous notice published in
the Federal Register on September 23,
1975, (40 FR 43745–46), all applicants
for registration to import a basic class of
any controlled substances in schedule I
or II are and will continue to be required
to demonstrate to the Deputy Assistant
Administrator, Office of Diversion
E:\FR\FM\16NON1.SGM
16NON1
64679
Federal Register / Vol. 72, No. 221 / Friday, November 16, 2007 / Notices
Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: November 6, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–22486 Filed 11–15–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II and prior
to issuing a registration under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with Title 21
Code of Federal Regulations (CFR),
1301.34(a), this is notice that on August
23, 2007, Formulation Technologies
LLC., 11400 Burnet Road, Suite 4010,
Austin, Texas 78758, made application
by renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of Fentanyl (9801), a basic
class of controlled substance listed in
schedule II.
The company plans to import the
listed controlled substance for clinical
trials, research, analytical purposes, and
distribution to its customers.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43
and in such form as prescribed by 21
CFR 1316.47.
Any such comments or objections
being sent via regular mail should be
addressed, in quintuplicate, to the Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), Washington, DC
20537, or any being sent via express
mail should be sent to Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), 8701 Morrissette
Drive, Springfield, VA 22152; and must
be filed no later than December 17,
2007.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e) and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substances in schedule I
or II are and will continue to be required
to demonstrate to the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: November 6, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–22496 Filed 11–15–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated June 26, 2007, and
published in the Federal Register on
July 5, 2007, (72 FR 36727–36728),
Aldrich Chemical Company, Inc., DBA
Isotec, 3858 Benner Road, Miamisburg,
Ohio 45342, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the basic classes
of controlled substances listed in
schedule I and II:
mstockstill on PROD1PC66 with NOTICES
Drug
Schedule
Cathinone (1235) .........................................................................................................................................................................................
Methcathinone (1237) ..................................................................................................................................................................................
N-Ethylamphetamine (1475) ........................................................................................................................................................................
N,N-Dimethylamphetamine (1480) ..............................................................................................................................................................
Aminorex (1585) ..........................................................................................................................................................................................
Gamma Hydroxybutyric Acid (2010) ...........................................................................................................................................................
Methaqualone (2565) ..................................................................................................................................................................................
Ibogaine (7260) ...........................................................................................................................................................................................
Lysergic acid diethylamide (7315) ...............................................................................................................................................................
Tetrahydrocannabinols (7370) .....................................................................................................................................................................
Mescaline (7381) .........................................................................................................................................................................................
2,5-Dimethoxyamphetamine (7396) ............................................................................................................................................................
3,4-Methylenedioxyamphetamine (7400) ....................................................................................................................................................
3,4-Methylenedioxy-N-ethylamphetamine (7404) ........................................................................................................................................
3,4-Methylenedioxymethamphetamine (7405) ............................................................................................................................................
4-Methoxyamphetamine (7411) ...................................................................................................................................................................
Psilocybin (7437) .........................................................................................................................................................................................
Psilocyn (7438) ............................................................................................................................................................................................
N-Ethyl-1-phenylcyclohexylamine (7455) ....................................................................................................................................................
Dihydromorphine (9145) ..............................................................................................................................................................................
Normorphine (9313) ....................................................................................................................................................................................
Acetylmethadol (9601) .................................................................................................................................................................................
Alphacetylmethadol except levo-alphacetylmethadol (9603) ......................................................................................................................
Normethadone (9635) .................................................................................................................................................................................
Norpipanone (9636) .....................................................................................................................................................................................
3-Methylfentanyl (9813) ...............................................................................................................................................................................
Amphetamine (1100) ...................................................................................................................................................................................
Methamphetamine (1105) ...........................................................................................................................................................................
Methylphenidate (1724) ...............................................................................................................................................................................
VerDate Aug<31>2005
21:48 Nov 15, 2007
Jkt 214001
PO 00000
Frm 00106
Fmt 4703
Sfmt 4703
E:\FR\FM\16NON1.SGM
16NON1
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
]]>Agencies
[Federal Register Volume 72, Number 221 (Friday, November 16, 2007)]
[Notices]
[Pages 64678-64679]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-22486]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to
issuing a registration under this Section to a bulk manufacturer of a
controlled substance in schedule I or II and prior to issuing a
registration under 21 U.S.C. 952(a)(2) authorizing the importation of
such a substance, provide manufacturers holding registrations for the
bulk manufacture of the substance an opportunity for a hearing.
Therefore, in accordance with Title 21 Code of Federal Regulations
(CFR), 1301.34(a), this is notice that on June 22, 2007, Fisher
Clinical Services Inc., 7554 Schantz Road, Allentown, Pennsylvania
18106, made application by renewal to the Drug Enforcement
Administration (DEA) to be registered as an importer of Noroxymorphone
(9668), a basic class of controlled substance listed in schedule II.
The company plans to import the listed substance for analytical
research and clinical trials.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic class of controlled
substance may file comments or objections to the issuance of the
proposed registration and may, at the same time, file a written request
for a hearing on such application pursuant to 21 CFR 1301.43 and in
such form as prescribed by 21 CFR 1316.47.
Any such comments or objections being sent via regular mail should
be addressed, in quintuplicate, to the Drug Enforcement Administration,
Office of Diversion Control, Federal Register Representative (ODL),
Washington, DC 20537, or any being sent via express mail should be sent
to Drug Enforcement Administration, Office of Diversion Control,
Federal Register Representative (ODL), 8701 Morrissette Drive,
Springfield, VA 22152; and must be filed no later than December 17,
2007.
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR Sec. 1301.34(b),
(c), (d), (e) and (f). As noted in a previous notice published in the
Federal Register on September 23, 1975, (40 FR 43745-46), all
applicants for registration to import a basic class of any controlled
substances in schedule I or II are and will continue to be required to
demonstrate to the Deputy Assistant Administrator, Office of Diversion
[[Page 64679]]
Control, Drug Enforcement Administration, that the requirements for
such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and
21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.
Dated: November 6, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E7-22486 Filed 11-15-07; 8:45 am]
BILLING CODE 4410-09-P
